Clinical-stage developer of PP353, a non-opioid, one-off therapeutic that targets the underlying cause of chronic low back pain with Modic changes rather than just symptoms. Phase 1b trial showed statistically significant and clinically meaningful reductions in pain and disability; currently in regulatory discussions to advance to registrational trials.